Last reviewed 2026-04-22 · How we verify

Loceryl NL 12 weeks

Galderma R&D · FDA-approved active Small molecule

Loceryl NL 12 weeks is a Allylamine antifungal Small molecule drug developed by Galderma R&D. It is currently FDA-approved for Onychomycosis (fungal nail infection), Dermatophyte and yeast infections of nails.

Loceryl is a topical antifungal that inhibits fungal sterol synthesis by blocking lanosterol 14α-demethylase, disrupting the fungal cell membrane.

Loceryl is a topical antifungal that inhibits fungal sterol synthesis by blocking lanosterol 14α-demethylase, disrupting the fungal cell membrane. Used for Onychomycosis (fungal nail infection), Dermatophyte and yeast infections of nails.

At a glance

Generic name	Loceryl NL 12 weeks
Sponsor	Galderma R&D
Drug class	Allylamine antifungal
Target	Lanosterol 14α-demethylase (CYP51)
Modality	Small molecule
Therapeutic area	Dermatology / Infectious Disease
Phase	FDA-approved

Mechanism of action

Amorolfine, the active ingredient in Loceryl, is an allylamine antifungal that interferes with ergosterol biosynthesis in fungal cell membranes. By inhibiting the cytochrome P450-dependent enzyme lanosterol 14α-demethylase, it causes accumulation of toxic sterol precursors and depletion of ergosterol, leading to fungal cell death. This mechanism makes it effective against dermatophytes, yeasts, and non-dermatophyte molds.

Approved indications

Onychomycosis (fungal nail infection)
Dermatophyte and yeast infections of nails

Common side effects

Local irritation or burning at application site
Nail discoloration or discomfort
Allergic contact dermatitis

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Loceryl NL 12 weeks CI brief — competitive landscape report
Loceryl NL 12 weeks updates RSS · CI watch RSS
Galderma R&D portfolio CI

Frequently asked questions about Loceryl NL 12 weeks

What is Loceryl NL 12 weeks?

Loceryl NL 12 weeks is a Allylamine antifungal drug developed by Galderma R&D, indicated for Onychomycosis (fungal nail infection), Dermatophyte and yeast infections of nails.

How does Loceryl NL 12 weeks work?

Loceryl is a topical antifungal that inhibits fungal sterol synthesis by blocking lanosterol 14α-demethylase, disrupting the fungal cell membrane.

What is Loceryl NL 12 weeks used for?

Loceryl NL 12 weeks is indicated for Onychomycosis (fungal nail infection), Dermatophyte and yeast infections of nails.

Who makes Loceryl NL 12 weeks?

Loceryl NL 12 weeks is developed and marketed by Galderma R&D (see full Galderma R&D pipeline at /company/galderma-r-d).

What drug class is Loceryl NL 12 weeks in?

Loceryl NL 12 weeks belongs to the Allylamine antifungal class. See all Allylamine antifungal drugs at /class/allylamine-antifungal.

What development phase is Loceryl NL 12 weeks in?

Loceryl NL 12 weeks is FDA-approved (marketed).

What are the side effects of Loceryl NL 12 weeks?

Common side effects of Loceryl NL 12 weeks include Local irritation or burning at application site, Nail discoloration or discomfort, Allergic contact dermatitis.

What does Loceryl NL 12 weeks target?

Loceryl NL 12 weeks targets Lanosterol 14α-demethylase (CYP51) and is a Allylamine antifungal.

Drug class: All Allylamine antifungal drugs
Target: All drugs targeting Lanosterol 14α-demethylase (CYP51)
Manufacturer: Galderma R&D — full pipeline
Therapeutic area: All drugs in Dermatology / Infectious Disease
Indication: Drugs for Onychomycosis (fungal nail infection)
Indication: Drugs for Dermatophyte and yeast infections of nails

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing